Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5
After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has successfully completed an over $3 million capital raise to support this next phase and further bolster the company’s robust patent portfolio. The financing round, which garnered strong interest from both new and existing investors, underscores […]